Redeye provides a research update following the Q2 2024 report from Kancera.
InfraCom’s report was weak, and the company faces a cocktail of headwinds.
Redeye states AVTECH’s report was in line with Redeye Research estimate (RRe) on net sales and a sol...
Q2 sales were in line, EBITDA 11% better Continues to scale well; sales +17%, opex +3% y-o-y Trading...
AcuCort (”AcuCort” eller ”Bolaget”) har publicerat Bolagets delårsrapport för det andra kvartalet 20...
Refine Group (”Refine”, ”koncernen” eller ”bolaget”) publicerade den 23 augusti 2024 bolagets delårs...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) har publicerat Koncernens delår...
Redeye provides a research update following the Q2 report published by Initiator Pharma earlier toda...
Lyckegård Group AB (”Lyckegård” eller ”Bolaget”) består fr.
Loihde reports its H1 results on August 27th. We expect slight net sales growth and a clear y/y prof...
Redeye sees a solid report with Q2 numbers mainly in-line with our expectations.
Redeye states the report was weak, and it is apparent that InfraCom struggles with its Connect acqui...
Tumorad-01 is progressing towards the DMC meeting and the study is about to expand the number of pat...
Redeye states the report was in line with preannounced figures and slightly ahead on sales with a 25...
Redeye comments on I-Tech’s Q2 figures that were stronger than our expectations in all regards.
